Before navigating today’s volatile market, leaders seeking to bridge the divide between discovery and enterprise value should read Dr. David H. Crean’s Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences. The book delivers an essential framework for executives, researchers, and board members to master both biological validation and complex corporate finance. By reading … Read more
This industry has a long tradition of softening the truth about what leadership failure actually costs. But if we look closely, we would realize that life sciences is a tournament, somewhat analogous to the NCAA’s March Madness. Out of every 10,000 potential drug compounds screened in preclinical research, only one will eventually receive FDA approval. … Read more
In biopharma, the most dangerous stretch of road is neither the initial hypothesis nor the final launch. It is the treacherous, capital-intensive space between early discovery and full-scale commercialization where hundreds of promising therapeutics go to die. While conventional wisdom points to clinical trial failures and unpredicted toxicity as the primary cause of death, you … Read more
Have you ever wondered why extraordinary scientific breakthroughs quietly vanish every year? A novel molecule demonstrates breathtaking target selectivity in vitro, cures disease models in mice, and generates glowing peer-reviewed papers in high-impact journals. Yet, three years later, the spinout behind it has quietly liquidated, the lab stands empty, and the intellectual property sits gathering … Read more